Navigation Links
St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

amivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

    Contact:

    BioCryst Pharmaceuticals, Inc.

    Jonathan M. Nugent

    V.P. Corporate Communications

    (205) 444-4633

CONTACT: Jonathan M. Nugent, V.P. Corporate Communications of BioCrystPharmaceuticals, Inc., +1-205-444-4633

Web site: http://www.biocryst.com/'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/31/2014)... , Oct. 31, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... September 30, 2014. "In the ... Doug Murphy-Chutorian , M.D., chief executive officer ...
(Date:10/31/2014)... Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, ... 30, 2014. Brian M. Culley, the ... productive for Mast. Consistent with prior guidance, our 388-patient pivotal ... is on track to complete enrollment by the end ... in the U.S. and more than ten study sites ...
(Date:10/31/2014)... Mich. , Oct. 31, 2014  Lycera ... modulators to treat autoimmune disease and cancer, today ... novel synthetic RORgamma agonist product candidates will be ... for Immunotherapy of Cancer (SITC) being held November ... Convention Center, National Harbor, MD.  The poster, entitled ...
Breaking Medicine Technology:Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2
... 2011 Emmy®-nominated actress Christina Hendricks, in partnership with Allergan, ... (bimatoprost ophthalmic solution) 0.03% is calling on women to help ... Make-A-Wish Foundation by November 30 through the LATISSE® Wishes ... tradition of blowing on an eyelash to make wishes come ...
... Now available for endoscopic dilation of the ... Corporation,s (NYSE: BSX ) CRE™ Wireguided Balloon ... the Sphincter of Oddi following sphincterotomy.  The new indication, ... the alimentary (digestive) tract, lets physicians perform Dilation Assisted ...
Cached Medicine Technology:Actress Christina Hendricks Urges Women to Join Her in the Final Weeks of the LATISSE® Wishes Challenge to Increase Money Raised for the Make-A-Wish Foundation® from $390,000 to Campaign Goal of $500,000 2Actress Christina Hendricks Urges Women to Join Her in the Final Weeks of the LATISSE® Wishes Challenge to Increase Money Raised for the Make-A-Wish Foundation® from $390,000 to Campaign Goal of $500,000 3Actress Christina Hendricks Urges Women to Join Her in the Final Weeks of the LATISSE® Wishes Challenge to Increase Money Raised for the Make-A-Wish Foundation® from $390,000 to Campaign Goal of $500,000 4Actress Christina Hendricks Urges Women to Join Her in the Final Weeks of the LATISSE® Wishes Challenge to Increase Money Raised for the Make-A-Wish Foundation® from $390,000 to Campaign Goal of $500,000 5Actress Christina Hendricks Urges Women to Join Her in the Final Weeks of the LATISSE® Wishes Challenge to Increase Money Raised for the Make-A-Wish Foundation® from $390,000 to Campaign Goal of $500,000 6Boston Scientific CRE™ Wireguided Balloon Dilator CE Marked for Expanded Indication 2Boston Scientific CRE™ Wireguided Balloon Dilator CE Marked for Expanded Indication 3Boston Scientific CRE™ Wireguided Balloon Dilator CE Marked for Expanded Indication 4
(Date:10/31/2014)... 2014 Daily Gossip writes in its Xtreme ... as the fastest fat loss program ever developed. It promises ... month. , There is no wonder after all that this ... time. The new nutrition and workout fat loss program was ... , According to the author of this fat loss ...
(Date:10/31/2014)... At the start of 2014, numerous news ... monoxide poisoning in their homes. Now, as 2015 (and ... Missouri-based heating and cooling company is taking a more ... the home heating season with the assurance that their ... Nov. 1, 2014, E and Q Heating and Cooling ...
(Date:10/31/2014)... 31, 2014 Energy Textiles has recently ... new gear is now available online, and Energy Textile ... of Celliant infrared-active athletic gear over compression gear. , ... contract has been signed for Under Armour to provide ... next eight years. In light of this decision, Energy ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Obesity increases the ... black and Hispanic women, two new U.S. studies show. ... found being overweight or obese increased the risk for ... women. "We,ve known this for a long time ... also in Hispanic women," study author Esther John, a ...
(Date:10/31/2014)... four older Americans say that either they or a ... according to the latest issue of The Gerontological Society ... ( PP&AR ), which goes on to show that ... to honor patients, end-of-life health care wishes. , This ... and Options ," features 12 articles that present new ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Advance directives can benefit patients, families, and health care system 2
... patient,s DNA may lead to routine gene scans, experts ... In a genetics first, researchers report that they have ... acute myelogenous leukemia. , There were some surprises -- ... genetic alterations, were associated with the blood cell cancer. ...
... The Medical College of Georgia announced today that it ... the Bill & Melinda Gates Foundation. The grant ... by Dr. Pandelakis A. Koni titled "Antibody-Dependent Cellular Cytotoxicity ... is one of 104 grants recently announced by the ...
... 5 Dialysis Corporation,of America (Nasdaq: DCAI ... secured,revolving credit facility with KeyBank National Association to ... agreement provides for both,base rate and LIBOR loans ... the bank,s base rate or the London InterBank ...
... WEXFORD, Pa., Nov. 5 Millennium Pharmacy Systems, ... Health Care Center in,Bridgeport, West Virginia, its first ... more than 100 facilities in four states: Pennsylvania,Maryland, ... Administrator, states, "The Millennium,system was more advanced than ...
... founded a state-of-the-art eye care facility in Tanzania ... BERKELEY, Calif., Nov. 5 Today, Seva,Foundation ... in,the fight against preventable blindness around the world ... Yesterday, the Kilimanjaro Center for Community Ophthalmology (KCCO),which ...
... The American Heart,Association and its Pharmaceutical Roundtable ... Research Centers initiative. The project,will provide a network ... results, or outcomes, of healthcare for people with ... The initiative is supported in part by a ...
Cached Medicine News:Health News:First-Ever Mapping of Cancer Patient's Genome 2Health News:First-Ever Mapping of Cancer Patient's Genome 3Health News:MCG receives $100,000 Grand Challenges Explorations grant for innovative global health research 2Health News:Dialysis Corporation of America Announces $25 Million Credit Facility 2Health News:Millennium Pharmacy Systems Expands into West Virginia 2Health News:Seva Foundation Recognizes Paul Courtright and Susan Lewallen for Their Commitment to Blindness Prevention 2Health News:Seva Foundation Recognizes Paul Courtright and Susan Lewallen for Their Commitment to Blindness Prevention 3Health News:Four Medical Centers Awarded Funds to Improve Outcomes Research for Heart Disease and Stroke 2
Toxoplasma IgM II ELISA....
HSV 1 & HSV 2 DFA Test....
Herpes Simplex Virus 2 IgG ELISA....
Herpes Simplex Virus 1 IgG ELISA....
Medicine Products: